Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera-Reference-Cited by-同舟云学术

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

Published:2024-02-22 Issue:8 Volume:390 Page:723-735
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Kremyanskaya Marina¹,Kuykendall Andrew T.¹,Pemmaraju Naveen¹,Ritchie Ellen K.¹,Gotlib Jason¹,Gerds Aaron¹,Palmer Jeanne¹,Pettit Kristen¹,Nath Uttam K.¹,Yacoub Abdulraheem¹,Molina Arturo¹,Saks Samuel R.¹,Modi Nishit B.¹,Valone Frank H.¹,Khanna Sarita¹,Gupta Suneel¹,Verstovsek Srdan¹,Ginzburg Yelena Z.¹,Hoffman Ronald¹

Affiliation:

1. From the Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (M.K., Y.Z.G., R.H.), and the Division of Hematology and Medical Oncology, Weill Cornell Medical College (E.K.R.) — both in New York; the Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL (A.T.K.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (N.P., S.V.); the Division of Hematology, Stanford Cancer Institute, Stanford...

Funder

Protagonist Therapeutics

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2308809

Reference35 articles.

1. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera

2. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views

3. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

4. A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders

5. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?;Expert Opinion on Pharmacotherapy;2024-08-12

2. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. The evolving landscape of polycythemia vera therapies;Expert Opinion on Pharmacotherapy;2024-07-23

4. Ein Hepcidin-Mimetikum zur Kontrolle der Erythrozytose;InFo Hämatologie + Onkologie;2024-07

5. Polycythemia vera: past, present and future;Leukemia & Lymphoma;2024-06-13